Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001950993 | SCV002240148 | pathogenic | Hereditary breast ovarian cancer syndrome | 2021-02-28 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Leu1598Glnfs*2) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with BRCA2-related conditions. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV002484799 | SCV002793875 | pathogenic | Familial cancer of breast; Breast-ovarian cancer, familial, susceptibility to, 2; Fanconi anemia complementation group D1; Medulloblastoma; Wilms tumor 1; Malignant tumor of prostate; Pancreatic cancer, susceptibility to, 2; Glioma susceptibility 3 | 2022-04-03 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV003453871 | SCV004190003 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2023-09-22 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |